American Cancer Society lung cancer screening guidelines.
Repository Usage Stats
Findings from the National Cancer Institute's National Lung Screening Trial established that lung cancer mortality in specific high-risk groups can be reduced by annual screening with low-dose computed tomography. These findings indicate that the adoption of lung cancer screening could save many lives. Based on the results of the National Lung Screening Trial, the American Cancer Society is issuing an initial guideline for lung cancer screening. This guideline recommends that clinicians with access to high-volume, high-quality lung cancer screening and treatment centers should initiate a discussion about screening with apparently healthy patients aged 55 years to 74 years who have at least a 30-pack-year smoking history and who currently smoke or have quit within the past 15 years. A process of informed and shared decision-making with a clinician related to the potential benefits, limitations, and harms associated with screening for lung cancer with low-dose computed tomography should occur before any decision is made to initiate lung cancer screening. Smoking cessation counseling remains a high priority for clinical attention in discussions with current smokers, who should be informed of their continuing risk of lung cancer. Screening should not be viewed as an alternative to smoking cessation. Copyright © 2013 American Cancer Society, Inc.
Published Version (Please cite this version)10.3322/caac.21172
Publication InfoSullivan, Daniel; Oeffinger, Kevin; Oeffinger, Kevin; Wender, R; Fontham, ETH; Barrera, E; ... Smith, RA (2013). American Cancer Society lung cancer screening guidelines. CA: a cancer journal for clinicians, 63(2). pp. 107-117. 10.3322/caac.21172. Retrieved from https://hdl.handle.net/10161/18038.
This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.
More InfoShow full item record
Professor of Medicine
Kevin Oeffinger, MD, is a family physician, a member of the Duke Cancer Institute (DCI), the founding Director of the DCI Center for Onco-Primary Care, and Director of the DCI Supportive Care and Survivorship Center. Prior to joining Duke in April 2017, Dr. Oeffinger was the Director of the Cancer Survivorship Center at Memorial Sloan Kettering Cancer Center. He has a long-standing track record of NIH-supported research in cancer screening and survivorship and has served in a leadership capac
Professor Emeritus of Radiology
Research interests are in oncologic imaging, especially the clinical evaluation and validation of imaging biomarkers for therapeutic response assessment.
Alphabetical list of authors with Scholars@Duke profiles.